Bovine Respiratory Syncytial Virus: Overview and Molecular Detection

Bovine respiratory syncytial virus belongs to the order Mononegavirales, family Paramyxoviridae, subfamily Pneumovirinae, and genus Pneumovirus. It is an enveloped, single-stranded, negative-sense RNA virus. Under electron microscopy, viral particles are pleomorphic and may appear spherical or filamentous, with diameters of approximately 60–100 nm and filament lengths reaching up to 5 μm.

The virus contains a helical nucleocapsid surrounded by an envelope with surface projections. Its genome is approximately 15–16 kb in length and encodes 10 mRNAs that produce 11 proteins, including NS1, NS2, N, P, M, SH, G, F, M2-1, M2-2, and L. The G, F, and SH proteins are major envelope components, while N, P, and L proteins are associated with the nucleocapsid. The virus lacks both hemagglutinin and neuraminidase activity.

BRSV is thermolabile and rapidly loses infectivity in protein-free solutions at 4°C or room temperature. It can be inactivated at 56°C within 30 minutes but may remain viable for months at -80°C. The virus is also sensitive to acid, alkali, ether, chloroform, deoxycholate, and trypsin. In cell culture, BRSV grows particularly well in bovine-derived respiratory cells, including bovine turbinate cells, and infection commonly induces the formation of multinucleated syncytia.

BRSV was first identified in Europe in 1970 and later in the United States in 1974. Since then, it has been widely recognized as one of the most important viral pathogens involved in bovine respiratory disease. Serological surveys have shown high antibody prevalence in both dairy and beef herds, indicating widespread circulation in cattle populations across different regions and production systems.

Both calves and adult cattle are susceptible to infection, and breeding bulls may also be affected. Infected bulls may show reduced semen quality, possibly due to secondary tissue damage rather than direct viral replication in semen. The virus may persist in herds through repeated introduction, viral evolution, or possible subclinical circulation, although the exact long-term maintenance mechanism in cattle populations remains incompletely understood.

Outbreaks occur under both epidemic and endemic conditions. In naïve herds, first exposure can cause obvious respiratory disease in adult cattle and replacement heifers. In enzootically infected herds, disease is often more severe in young stock, especially during winter and spring. Environmental stress, herd mixing, and co-infections can all contribute to disease spread and severity.

Clinical signs of BRSV infection range from mild respiratory disease to severe outbreaks with high morbidity. Common symptoms include depression, reduced appetite, high fever, nasal discharge, salivation, coughing, tachypnea, dyspnea, and open-mouth breathing. In lactating cows, milk production may decrease, while calves often show poor growth and delayed development.

Some severe cases exhibit a biphasic fever pattern. During the first phase, animals may show relatively mild symptoms and partial improvement with supportive treatment. However, several days later, the disease may worsen abruptly, and this second phase is often more difficult to control and may lead to death. In some cattle, subcutaneous emphysema over the back may also be observed.

Pathologically, lesions are concentrated mainly in the cranial and ventral lung lobes and may include congestion, consolidation, collapse, emphysema, and pulmonary edema. Histologically, the disease is characterized by exudative and proliferative bronchiolitis, epithelial necrosis, syncytium formation, inflammatory cell infiltration, alveolar collapse, and interstitial pneumonia. In severe cases, hyaline membrane formation and atypical interstitial pneumonia-like lesions may occur.

Traditional diagnostic methods for BRSV include virus isolation, fluorescent antibody testing, enzyme immunoassays, indirect immunofluorescence, immunohistochemistry, and serology. Virus isolation remains a classical method but is labor-intensive, time-consuming, and technically unstable. Antigen detection methods may provide faster results but can be affected by sample quality, tissue autolysis, and assay sensitivity.

Serological diagnosis can be helpful because acute infection often induces a rapid rise in antibody titers, with peak levels commonly reached within two weeks. Comparison of paired serum samples can therefore support diagnosis in herd investigations.

Molecular testing has become the most reliable diagnostic approach. Reverse transcription PCR, nested RT-PCR, and real-time RT-PCR have all been used for BRSV detection, with probe-based real-time RT-PCR generally offering the highest sensitivity and specificity. These methods enable rapid detection of viral RNA in nasal secretions, lung tissue, or other respiratory samples and are now widely regarded as the preferred laboratory standard for BRSV diagnosis.

There is no specific antiviral treatment for BRSV. Clinical management is based on supportive care and prevention of secondary bacterial infections. Because affected cattle often lose fluids and electrolytes, oral or intravenous replacement may be necessary. Broad-spectrum antibiotics are commonly used to control bacterial co-infections such as Pasteurella multocida or Histophilus somni, ideally guided by herd history or laboratory susceptibility data.

Nonsteroidal anti-inflammatory drugs may help reduce fever and improve clinical comfort in acute cases. Antihistamines, atropine, and diuretics may be considered in selected cases with respiratory distress or pulmonary edema. Corticosteroids may temporarily reduce clinical signs but must be used cautiously because of their immunosuppressive effects and the risk of worsening tissue damage or causing abortion in pregnant cattle.

Vaccination is the most effective preventive strategy. Early inactivated vaccines were associated with poor protection and in some cases enhanced disease, whereas modified vaccine approaches and live attenuated vaccines have shown improved ability to induce neutralizing antibodies. The F protein is considered a major immunogenic target for protective immunity. In herd management, vaccination programs combined with biosecurity, colostrum management, and early molecular detection can greatly reduce the impact of BRSV.